Multidisciplinary management of acromegaly: a consensus
Abstract The 13th Acromegaly Consensus Conference was held in November 2019 in Fort
Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and …
Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and …
Acromegaly: pathogenesis, diagnosis, and management
M Fleseriu, F Langlois, DST Lim… - The Lancet Diabetes & …, 2022 - thelancet.com
Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …
A Pituitary Society update to acromegaly management guidelines
M Fleseriu, BMK Biller, PU Freda, MR Gadelha… - Pituitary, 2021 - Springer
Guidelines and consensus statements ensure that physicians managing acromegaly
patients have access to current information on evidence-based treatments to optimize …
patients have access to current information on evidence-based treatments to optimize …
Diagnosis and treatment of acromegaly: an update
N Ershadinia, NA Tritos - Mayo Clinic Proceedings, 2022 - Elsevier
Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …
Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission …
Recurrence and biochemical remission rates vary widely among different histological
subtypes of pituitary adenoma. In this prospective study, we evaluated 107 consecutive …
subtypes of pituitary adenoma. In this prospective study, we evaluated 107 consecutive …
Personalized medical treatment of patients with acromegaly: a review
DST Lim, M Fleseriu - Endocrine Practice, 2022 - Elsevier
Acromegaly is associated with significant morbidity and mortality if it is not appropriately
treated. In addition to insulin-like growth factor 1 and growth hormone normalization as well …
treated. In addition to insulin-like growth factor 1 and growth hormone normalization as well …
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly
A Tomasik, M Stelmachowska-Banaś… - Frontiers in …, 2022 - frontiersin.org
Background Transsphenoidal adenomectomy (TSS) of somatotroph pituitary
neuroendocrine tumor (PitNET) is the first-line treatment of acromegaly. Pharmacological …
neuroendocrine tumor (PitNET) is the first-line treatment of acromegaly. Pharmacological …
Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on …
OBJECTIVE Treatment outcomes following initial transsphenoidal surgery (TSS) for
acromegaly are erratic. Identifying outcome patterns can assist in informing patients about …
acromegaly are erratic. Identifying outcome patterns can assist in informing patients about …
Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study
EC Coopmans, MR Postma, TLC Wolters… - The Journal of …, 2021 - academic.oup.com
Context Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It
is important to identify patients in whom surgical cure is not attainable at an early stage, both …
is important to identify patients in whom surgical cure is not attainable at an early stage, both …
Cytodifferentiation of pituitary tumors influences pathogenesis and cavernous sinus invasion
OBJECTIVE Pituitary tumors (PTs) continue to present unique challenges given their
proximity to the cavernous sinus, whereby invasive behavior can limit the extent of resection …
proximity to the cavernous sinus, whereby invasive behavior can limit the extent of resection …